National Toxicology Program

National Toxicology Program

Testing Status of AZT + Rifampin (AIDS Initiative) - M930017




  • 30516-87-1 - 3'-Azido-3'-deoxythymidine (AIDS)
  • 30516-87-1 - AZT transplacental carcinogenesis study
  • 13292-46-1 - Rifampin

Known Uses

Drug combination to be used as AIDS therapy

Short-Term Toxicity

  • 13 weeks (Gavage)  (C93002)  Completed 
    • Mice: B6C3F1

Special Studies

  • Toxicokinetic Study (Gavage; Intravenous)  (S0553)  Completed 
    • Male and Female Mice: B6C3F1
  • Toxicokinetic Study (Gavage; Intravenous)  (S0643)  Completed 
    • Citation: The Effect of Multiply Administered Rifampicin (RIF) on the Toxicokinetics and Metabolism of 3'-Azido-Deoxythymidine (AZT) in Male and Female B6C3F1 Mice.
    • Male and Female Mice: B6C3F1
NTP is located at the National Institute of Environmental Health Sciences, part of the National Institutes of Health.